(NASDAQ: BCEL) Atreca's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 9.1%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 16.41%.
Atreca's earnings in 2022 is -$109,629,000.On average, 7 Wall Street analysts forecast BCEL's earnings for 2022 to be -$105,740,535, with the lowest BCEL earnings forecast at -$113,072,907, and the highest BCEL earnings forecast at -$95,706,761. On average, 7 Wall Street analysts forecast BCEL's earnings for 2023 to be -$96,092,676, with the lowest BCEL earnings forecast at -$130,053,139, and the highest BCEL earnings forecast at -$77,182,872.
In 2024, BCEL is forecast to generate -$101,495,477 in earnings, with the lowest earnings forecast at -$117,317,965 and the highest earnings forecast at -$92,619,446.